Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Is Royal Caribbean Group a Winning Stock in the Travel Services Industry?

Published 11/12/2021, 08:24 AM
Updated 11/12/2021, 09:30 AM
© Reuters.  Is Royal Caribbean Group a Winning Stock in the Travel Services Industry?

Cruise operator Royal Caribbean’s (RCL) shares surged in price last week after Pfizer shared positive results for its COVID-19 oral antiviral treatment candidate, which was found to reduce the risk of hospitalization or death by 89%. However, the stock has slumped 8.2% over the past five days. Also, given that RCL is currently trading at a lofty valuation, is the stock worth betting on now? Read on.The world's second-largest cruise company, Royal Caribbean Cruises Ltd. (NYSE:RCL), which is based in Miami, Fla., owns three global cruise vacation brands, including Royal Caribbean International, Celebrity Cruises, and Silversea Cruises. Its brands operate approximately 58 ships with an additional 15 on order. Its stock has gained 20.4% in price over the past year and 18.8% year-to-date to close yesterday’s trading session at $86.30. However, the shares are currently trading below their 50-day moving average. And over the past five days, RCL has retreated 8.2%.

The company incurred massive losses last year due to pandemic-related travel restrictions. But recently announced positive data from Pfizer Inc. (NYSE:PFE) for its COVID-19 oral antiviral treatment candidate, which was found to reduce the risk of hospitalization or death by 89%, buoyed investors’ optimism about the recovery of the cruise industry. RCL shares advanced following the news release. Furthermore, if the breakthrough drug does reduce fatalities, the demand for travel should rebound and enable cruise line companies, including RCL, to reverse their fortunes.

The company expects to generate positive cash flow by spring and be profitable for the entire year of 2022. However, operational challenges persist, and the demand rebound is uncertain because the possibility of new variants of the virus emerging cannot be ruled out. Also, the commercialization of the Pfizer drug is expected to take a while. Also, RCL looks significantly overvalued at its current price level, considering its underlying fundamentals and, with a 2.62 beta, the stock seems to be highly volatile.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Continue reading on StockNews

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.